drugset / Trial / NCT00386100

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100

Phase 4 Completed 688 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the longer-term glycemic effect of two medicines approved for initial treatment of type 2 diabetes. The study consists of a 2 week screening period (2 study visits), followed by an 80 week double-blind treatment period (11 study visits). Also, a sub-study was included to look at changes in bone mineral density (BMD) at the lumbar spine.

Timeline

Start
2006-10
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metformin Small molecule 500 mg
Comparator Metformin Small molecule 1000 mg
Comparator Metformin Small molecule 1500 mg
Comparator Metformin Small molecule 2000 mg
Comparator Rosiglitazone Small molecule 2 mg
Comparator Rosiglitazone Small molecule 4 mg
Comparator Rosiglitazone Small molecule 6 mg
Comparator Rosiglitazone Small molecule 8 mg